Zobrazeno 1 - 10
of 72
pro vyhledávání: '"James L. Kepner"'
Autor:
Man Jin, James L Kepner
Publikováno v:
International Journal of Clinical Biostatistics and Biometrics. 3
Autor:
James L. Kepner, Jihnhee Yu
Publikováno v:
Statistics & Probability Letters. 81:829-835
For testing “univariate” binomial proportions, it has been proven that, under mild conditions, there exist group sequential designs which satisfy the pre-specified Type I error and power of the single-stage design while the sample size is bounded
Autor:
James L. Kepner
Publikováno v:
Journal of Biopharmaceutical Statistics. 20:145-159
Discussed is the problem of sample size determination for one- and two-stage hypothesis tests comparing two binomial proportions using two independent random samples. A FORTRAN compiled search algorithm identifies exact group sequential designs that
Autor:
Nancy Soehnlein, Boris W. Kuvshinoff, James L. Kepner, Marwan Fakih, John F. Gibbs, Milind Javle, Renuka Iyer, David Lawrence
Publikováno v:
Annals of Surgical Oncology. 14:3202-3209
To determine the clinical benefit response (CBR), time to tumor progression (TTP), overall survival, and effect on quality of life (QOL) of gemcitabine and capecitabine in patients with advanced biliary cancer. Gemcitabine (1000 mg/m2 IV over 30 minu
Publikováno v:
Statistics & Probability Letters. 77:288-294
Exact power calculations to jointly test two correlated binomial outcomes are discussed using Biswas and Hwang's bivariate binomial distribution. We prove that power is a non-decreasing function of correlation. The method is extended to two-stage exa
Autor:
Zhengjia Chen, Paul G. Fisher, Carolyn R. Freeman, James L. Kepner, Cynthia Kretschmar, David N. Korones, Tianni Zhou
Publikováno v:
Pediatric Blood & Cancer. 50:227-230
Background The prognosis for children with brain stem glioma remains grim. Based on studies suggesting efficacy of vincristine and oral VP-16, The Pediatric Oncology Group (POG, now part of the Children's Oncology Group) conducted a study using these
Autor:
Trent D. Buskirk, Kevin Stein, C. Christina Bahn Mehta, Jeremy Stafford, Chiewkwei Kaw, James L. Kepner, Frank Baker, Tenbroeck Smith
Publikováno v:
Cancer. 109:1-12
The American Cancer Society (ACS) defines cancer survivorship as beginning at diagnosis with cancer and continuing for the balance of life and views quality of life (QOL) as a key outcome. In this article, the authors describe the rationale, methodol
Autor:
W. Dana Flanders, Elizabeth Ward, Amy Y. Chen, Nicole M. Schrag, Andrew K. Stewart, Yongping Hao, James L. Kepner
Publikováno v:
Otolaryngology–Head and Neck Surgery. 135:831-837
Objective In 1991, a randomized study was published and demonstrated that use of nonsurgical therapy (chemoradiation) provided similar survival to total laryngectomy (the gold standard) for patients with advanced-stage laryngeal cancer. The purpose o
Autor:
Jakob Dupont, Sally Schneider, Felicia Derosa, P. O. Livingston, Shashikant Lele, William P. McGuire, David R. Spriggs, Alexia Iasonos, S. Anderson, Martee L. Hensley, Soldano Ferrone, Paul Sabbatini, James L. Kepner, Cathy Grande, Kerry J. Rodabaugh, Carol Aghajanian, Silke Reinartz, Kunle Odunsi, Elizabeth A. Poynor
Publikováno v:
Clinical Cancer Research. 12:5503-5510
Purpose: This open-label study assessed the safety and immunogenicity of two doses and two routes of the anti-idiotypic monoclonal antibody abagovomab (formerly ACA125) in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer
Radiotherapy in pediatric medulloblastoma: Quality assessment of Pediatric Oncology Group Trial 9031
Autor:
Zhengjia Chen, Sandy Kessel, Tianni Zhou, Marcia Urie, James L. Kepner, Thomas J. Fitzgerald, Larry E. Kun, Patrick D. Barnes, Arvin S. Glicksman, Raymond Miralbell, Nancy J. Tarbell, Henry S. Friedman, Fran Laurie
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 64:1325-1330
Purpose: To evaluate the potential influence of radiotherapy quality on survival in high-risk pediatric medulloblastoma patients. Methods and Materials: Trial 9031 of the Pediatric Oncology Group (POG) aimed to study the relative benefit of cisplatin